CN107951940B - Blood pressure lowering medicine composition - Google Patents
Blood pressure lowering medicine composition Download PDFInfo
- Publication number
- CN107951940B CN107951940B CN201711138084.5A CN201711138084A CN107951940B CN 107951940 B CN107951940 B CN 107951940B CN 201711138084 A CN201711138084 A CN 201711138084A CN 107951940 B CN107951940 B CN 107951940B
- Authority
- CN
- China
- Prior art keywords
- parts
- total
- blood pressure
- effect
- hydrochlorothiazide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
Abstract
The invention discloses a blood pressure lowering pharmaceutical composition, which comprises the following components in parts by weight: 6-15 parts of hydrochlorothiazide, 160 parts of gambir plant total alkali, 25-50 parts of pueraria flavonid and 25-50 parts of magnolia officinalis total phenol, and belongs to the field of pharmacy. The method screens the dosage of hydrochlorothiazide, the total flavonoids of kudzuvine root and the total alkaloids of uncaria, redetermines the mixture ratio of the three components, and then adds a proper amount of the total magnolol on the basis, and the result shows that the improvement leads the total magnolol to generate obvious synergistic effect with the original three components, can more obviously reduce the systolic pressure and diastolic pressure of a test animal, can also inhibit an organism from generating drug resistance, leads the pressure reduction effect to be more durable, and does not lead the drug effect to be reduced along with the prolonging of the medication time.
Description
Technical Field
The invention belongs to the field of pharmacy, and relates to a blood pressure reducing pharmaceutical composition.
Background
Hypertension (EH) is a common cardiovascular disease and one of ten diseases recognized worldwide. The number of hypertension patients is about 10 hundred million worldwide, the prevalence rate of hypertension in China is 18.8 percent, and the prevalence rate of hypertension patients exceeds 1.6 hundred million. Hypertension is a significant risk factor for the development of heart attacks, strokes, renal failure and other cardiovascular diseases. The hypertension seriously harms the physical and mental health of people, weakens the labor capacity, reduces the life quality, is difficult to be radically cured and is easy to be repeatedly attacked, so the prevention and the treatment of the hypertension are not slow, and the research and the development of the high-efficiency and safe antihypertensive drug are important subjects of the research on the prevention and the treatment of the hypertension at present. The hypotensor used clinically at present is mainly western medicine, and has the main characteristics of quick response aiming at target-point symptomatic treatment, small daily dose, less frequency and relatively large side effect. The traditional Chinese medicine is used for treating hypertension, focuses on regulating the body function and treats both principal and secondary aspects of diseases, has mild effect and relatively small side effect, but has large dose, more times and slow effect after being taken every day. Chinese medicine resources are rich, and Chinese medicines with the function of reducing blood pressure are various, so that the Chinese medicine has great application and development prospects.
CN 101297884A discloses a concentrated blood pressure lowering maijunan tablet or capsule with small taking dosage, the active ingredients of which are 7 to 9 weight portions of hydrochlorothiazide, 280 weight portions of kudzuvine root total flavonoids and 140 weight portions of gambir plant total alkaloids. However, the medicine has poor blood pressure reducing effect in clinical application, and the blood pressure reducing effect is gradually reduced along with the prolonging of the medication time, which may be related to the generation of medicine resistance of human bodies.
Disclosure of Invention
The invention aims to provide a blood pressure reducing pharmaceutical composition with more obvious blood pressure reducing effect and more lasting effect.
The invention provides a blood pressure reducing pharmaceutical composition which comprises the following components in parts by weight: 6-15 parts of hydrochlorothiazide, 160 parts of gambir plant total alkali, 25-50 parts of pueraria flavonid and 25-50 parts of magnolia officinalis total phenol.
Preferably, the antihypertensive drug composition consists of the following components in parts by weight: 10 parts of hydrochlorothiazide, 132 parts of uncaria rhynchophylla total alkaloid, 36 parts of pueraria flavonid and 36 parts of magnolia officinalis total phenol.
The invention is improved on the basis of the concentrated blood pressure reducing maijunan tablets or capsules disclosed in CN 101297884A, firstly, the dosage of hydrochlorothiazide, pueraria flavonid and uncaria rhynchophylla total alkali is screened, the proportion of the three components is re-determined, then, a proper amount of magnolia officinalis total phenol is added on the basis, and the result is an unexpected finding that the magnolia officinalis total phenol not only generates obvious synergistic effect with the original three components, can more obviously reduce the systolic pressure and diastolic pressure of a test animal, but also can inhibit an organism from generating drug resistance, so that the blood pressure reducing effect is more durable, and the drug effect cannot be reduced along with the prolonging of the medication time.
The pharmaceutical composition provided by the invention can be used for preparing various blood pressure lowering medicines suitable for clinical use, especially oral medicines, such as tablets, capsules, granules, pills, oral liquid preparations and the like, when the pharmaceutical preparation is prepared, appropriate pharmaceutical excipients, such as a filler, a disintegrating agent, a lubricant, an adhesive and the like, are required to be added into the composition, and the selection of appropriate pharmaceutical excipients according to the required dosage form is a conventional means which can be mastered by a person skilled in the art.
The further preferable preparation formulation of the invention is a tablet or a capsule, and the two preparation formulations have the advantages of convenient taking, quick response, low production cost and the like.
Drawings
FIG. 1 is a graph showing the change in systolic blood pressure of SHR rats before and after administration.
FIG. 2 is a graph showing the change in diastolic pressure of SHR rats before and after administration of the drug.
Detailed Description
The present invention will be described in detail below with reference to examples.
Example 1
Animal grouping and treatment: 20 male essential hypertension rats (SHR) with blood pressure (186.3 + -6.3) mmHg were randomly divided into control group and test group. Test drugs and control drugs were administered to each group on a normal feed basis.
Test drugs: 10g of hydrochlorothiazide, 132g of uncaria rhynchophylla total alkaloid, 36g of pueraria flavonid and 36g of magnolia officinalis total phenol, and the raw material powders are uniformly mixed.
Control drug: 8g of hydrochlorothiazide, 120g of uncaria rhynchophylla total alkaloid and 260g of pueraria flavonid, and the raw material powder is uniformly mixed.
The test drug and the control drug are both administered at 100mg/kg, and the gavage is carried out once at 9-10 am every day for 8 weeks continuously.
Systolic and diastolic blood pressure of each group of rats was measured before and 1, 2, 4, 6, and 8 weeks after the administration, and the measurement was repeated 5 times or more.
The data from each set of experiments are expressed as (X. + -. S), and the statistical software SPSS 13.0 is used to perform a t-test analysis of variance for the set design, comparing the differences between the sets.
Results of the experiment
(1) Effect of drug on systolic blood pressure in SHR rats
Compared with the blood pressure of 0 week, the systolic pressure of the control group and the test group is decreased within 1-8 weeks after the drug administration, but the blood pressure decreasing effect of the control group only in the first 2 weeks is significantly different from that of the 0 week (p < 0.05), the systolic pressure of the 4 th-8 weeks is decreased but not much different from that of the 0 week (p >0.05), and the systolic pressure of the control group tends to gradually increase from the 4 th week. It shows that the rats resist the drugs with the prolonging of the medication time, which results in the reduction of the antihypertensive effect. The blood pressure reducing effect of the test group in eight weeks is significantly different from that in 0 week (p is less than 0.05), and the contraction pressure of the small (big) mice is still reduced until 8 weeks, and no rebound is seen. Therefore, compared with the control group, the test group has better antihypertensive effect and can prevent the body from generating drug resistance to reduce the drug effect. The detailed data are shown in table 1 and fig. 1.
TABLE 1 systolic blood pressure changes (X + -S, n-10) before and after long-term administration in each group of SHR rats
Note: compared with the blood pressure at the 0-week period,#p is less than 0.05.
(2) Effect of drug on diastolic pressure in SHR rats
Compared with the blood pressure of 0 week, the diastolic pressure of the control group is reduced within 1-8 weeks after the drug administration, but the blood pressure reducing effect of the control group is significantly different from that of the control group in the first 4 weeks (p < 0.05), the diastolic pressure of the control group is reduced but not greatly different from that of the control group in the 6 th-8 weeks (p >0.05), and the diastolic pressure of the control group tends to gradually increase from the fourth week. It shows that the rats resist the drugs with the prolonging of the medication time, which results in the reduction of the antihypertensive effect. The blood pressure reducing effect of the test group in eight weeks is significantly different from that in 0 week (p is less than 0.05), and the diastolic pressure of the rats is still reduced until 8 weeks without rebound. Therefore, compared with the control group, the test group has better antihypertensive effect and can prevent the body from generating drug resistance to reduce the drug effect. The detailed data are shown in table 2 and fig. 2.
Table 2 change in diastolic blood pressure of SHR rats in each group before and after long-term administration (X ± S, n ═ 10)
Note: compared with the 0 week blood pressure, # is p < 0.05.
Example 2
Taking 10g of hydrochlorothiazide, 132g of uncaria rhynchophylla total alkali and 36g of pueraria flavonid, respectively adding 20g, 25g, 30g, 35g, 40g, 45g, 50g and 55g of magnolia officinalis total phenol, and measuring the systolic blood pressure of each group of rats after 8 weeks of gastric lavage of SHR rats and 1, 2, 4, 6 and 8 weeks, wherein the results are shown in a table 3.
Table 3 systolic blood pressure changes (X ± S, n ═ 10) in each group of SHR rats before and after long-term administration
From the above results, it can be seen that when the total phenol content of Magnolia officinalis is 20g, the systolic blood pressure at week 6-8 is obviously increased, and the effect of preventing drug resistance is not achieved; when the total phenol content of the magnolia officinalis is 25-50g, the systolic pressure can be reduced, and the return rise of the systolic pressure can be prevented, wherein the comprehensive effect is best when the total phenol content of the magnolia officinalis is about 35 g.
Claims (4)
1. The blood pressure lowering medicine composition is characterized by comprising the following components in parts by weight: 10 parts of hydrochlorothiazide, 132 parts of uncaria rhynchophylla total alkaloid, 36 parts of pueraria flavonid and 36 parts of magnolia officinalis total phenol.
2. Use of the pharmaceutical composition of claim 1 for the preparation of a medicament for lowering blood pressure.
3. Use according to claim 2, characterized in that: the blood pressure lowering medicine is an oral preparation.
4. Use according to claim 3, characterized in that: the oral preparation is a tablet or a capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711138084.5A CN107951940B (en) | 2017-11-16 | 2017-11-16 | Blood pressure lowering medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711138084.5A CN107951940B (en) | 2017-11-16 | 2017-11-16 | Blood pressure lowering medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107951940A CN107951940A (en) | 2018-04-24 |
| CN107951940B true CN107951940B (en) | 2020-07-10 |
Family
ID=61964920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711138084.5A Expired - Fee Related CN107951940B (en) | 2017-11-16 | 2017-11-16 | Blood pressure lowering medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107951940B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109528707B (en) * | 2018-11-28 | 2021-02-09 | 湖北大学 | Antihypertensive medicinal composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101297884A (en) * | 2008-06-27 | 2008-11-05 | 湖北大学 | Prescription of low-dose condensed type Mai jun an tablet or capsule and preparation thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004175680A (en) * | 2002-11-25 | 2004-06-24 | Marine Bio Kk | Mineral-containing composition having improving effect on biological balance |
-
2017
- 2017-11-16 CN CN201711138084.5A patent/CN107951940B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101297884A (en) * | 2008-06-27 | 2008-11-05 | 湖北大学 | Prescription of low-dose condensed type Mai jun an tablet or capsule and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| "升降对药的应用(葛根与厚朴)";郭腾等;《中医药研究》;19951231(第4期);第43页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107951940A (en) | 2018-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145158B (en) | Ginger and clove composition, preparation method of ginger and clove composition and use of ginger and clove composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
| CN102091315B (en) | Ginger and dark plum fruit composition and preparation method thereof, and application of ginger and dark plum fruit composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN102166338B (en) | Alpinia katsumadai-ginger composite, preparation method thereof and use thereof for preparing toxicity-attenuating and effect-increasing medicine for radiotherapy and chemotherapy of cancer | |
| JP2013532666A (en) | Anti-fatigue composition, its formulation and application | |
| CN101264311B (en) | Natural pharmaceutical composition, its preparation and its attenuation synergistic use in cancer radiotherapy and chemotherapy | |
| CN110960624A (en) | Anti-fatigue composition and preparation method thereof | |
| CN101607036B (en) | Application of Chinese medicinal composition on in preparing medicament for treating depression | |
| CN107951940B (en) | Blood pressure lowering medicine composition | |
| EP0629400A1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| JPH0436243A (en) | Hypnotic sedative | |
| CN102085344A (en) | Aplotaxis carminative sustained-release preparation and preparation method thereof | |
| CN101966191A (en) | Amlodipine- and telmisartan-containing compound preparation for curing high blood pressure | |
| CN107007614A (en) | The medical usage of cycloastragenol | |
| KR20150037890A (en) | Compositions for treatment of cancer-related fatigue | |
| CN102091313B (en) | Composition of perilla leaf and ginger, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer | |
| CN107213197A (en) | A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared | |
| CN102641357A (en) | Medicament for treating hypertension and preparation method thereof | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN102552847B (en) | Ginger and inula flower composition for reducing vomiting caused by cancer chemotherapy and increasing curative effect for chemotherapy and preparing method thereof | |
| CN101450063A (en) | Oral medicine for treating hypochondria | |
| CN101683458B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo | |
| CN106943390B (en) | Application of the Strychnos nux-vomica aglycon in preparation prevention or treatment antiarrhythmic medicament | |
| CN103655969A (en) | Traditional Chinese medicine composition with functions of regulating blood pressure and blood glucose and preparation method thereof | |
| KR102482128B1 (en) | Compositions containing new methylsulfonylmethane(MSM) with increased arthritis treatment effect and the process of manufacture thereof | |
| CN102552481A (en) | Traditional Chinese medicinal composition with effects of smoothing collaterals and lowering blood pressure and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200710 Termination date: 20201116 |